Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease.

ABSTRACT:

Background

Overactive bladder (OAB) is a common non-motor symptom of Parkinson disease (PD), often treated with antimuscarinics or beta-3 agonists. There is lack of evidence to guide OAB management in PD.

Objectives

To assess the comparative safety of antimuscarinics versus beta-3 agonists for OAB treatment in PD.

Methods

We employed a new-user, active-comparator cohort study design. We included Medicare beneficiaries age ≥65 years with PD who were new users of either antimuscarinic or beta-3 agonist. The primary outcome was any acute care encounter (i.e., non-elective hospitalization or emergency department visit) within 90 days of OAB drug initiation. The main secondary outcome was a composite measure of acute care encounters for anticholinergic related adverse even

SUBMITTER: Abraham DS 

PROVIDER: S-EPMC10853986 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature